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Abstract
Without clinical guideline on the opti-
mal timing for primary total hip replace-
ment (THR), patients often receive the
operation with delay. Delaying THR may
negatively affect long-term health-related
quality of life, but its economic effects are
unclear. We evaluated the costs and health
benefits of timely primary THR for func-
tionally independent adult patients with
end-stage osteoarthritis (OA) compared to
non-surgical therapy followed by THR after
progression to functional dependence
(delayed THR), and non-surgical therapy
alone (Medical Therapy), from a German
Social Health Insurance (SHI) perspective.
Data from hip arthroplasty registers and a
systematic review of the published litera-
ture were used to populate a tunnel-state
modified Markov lifetime model of OA
treatment in Germany. A 5% annual dis-
count rate was applied to costs (2013
prices) and health outcomes (Quality
Adjusted Life Years, QALY). The expected
future average cost of timely THR, delayed
THR and medical therapy in women at age
55 were €27,474, €27,083 and €28,263, and
QALYs were 20.7, 16.7, and 10.3, respec-
tively. QALY differences were entirely due
to health-related quality of life differences.
The discounted cost per QALY gained by
timely over delayed (median delay of 11
years) THR was €1270 and €1338 in
women treated at age 55 and age 65, respec-
tively, and slightly higher than this for men.
Timely THR is cost-effective, generating
large quality of life benefits for patients at
low additional cost to the SHI. With declin-
ing healthcare budgets, research is needed
to identify the characteristics of those able
to benefit the most from timely THR.
Introduction
Besides patient preference, access to
primary total hip replacement (THR) for
patients with severe hip osteoarthritis (OA)
is determined by clinicians’ perceptions of
risks of surgical complications and implant
failure.1-3 In England, budgetary pressures
are also leading to increased rationing.4
While some patients may benefit from
delaying surgery,5 on average patients aged
50 and older may be better off by undergo-
ing surgery as soon as becoming eligible for
THR (timely THR) and while still function-
ally independent.3 It is unclear, however,
who should be offered THR, and guidelines
only state that eligible patients are those
that have chronic pain that is not controlled
by medication and non-medical therapies.2
Delaying surgery has the two-fold
advantage of reducing the risk of revision
occurrence, and increasing the expected
health improvement, since THR produces
larger quality of life gains in patients with
more severe disease.6 However, it imposes
quality of life losses on patients’ health dur-
ing the delay, and inferior quality of life
outcomes post-operatively relative to timely
surgery.3,7
Despite concerns that 14% of patients
do not report improvement after THR,8-11
there is increasing utilization of hip replace-
ment, driven by clinical need,12 and demo-
graphic change.13 While there is evidence
on the potential cost-effectiveness of timely
THR,3,14 no evidence on this question exists
for Germany.
This study sought to evaluate cost-
effectiveness of primary hip replacement in
Germany. It compared three treatment
options for a patient with end-stage
osteoarthritis: timely total primary hip
replacement, delayed total hip replacement,
and non-surgical therapy from the perspec-
tive of the statutory health insurer.
Materials and Methods
Decision analytic model
A Markov model previously published3
was adapted to Germany. Its structure is
illustrated in Figure 1, depicting a cohort of
functionally independent [American
College of Rheumatologists (ACR) class
III] patients with severe OA undergoing pri-
mary THR surgery. The alternative, to
remain under non-surgical therapy with
non-steroidal anti-inflammatory drugs
(NSAIDs), involves two mutually exclusive
options, namely, to delay therapy until dis-
ease progression to functional dependency
(ACR class IV) or a lifetime without opera-
tion. Conditional on the choice of treatment
and baseline patient age the model repre-
sents a series of annual contingent transi-
tions to different health states until death. In
each cycle the patient incurs costs and
accrues value (utility) from health-related
quality of life (HRQoL) in the state occu-
pied.
Following primary THR, the patient
may die as a result of surgery or survive the
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operation (Success state). The following
year a survivor may experience implant
failure, and therefore need for revision
operation, or remain in the Success state.
The former eventuality is associated with a
temporary (1-year period) deterioration in
HRQoL, and increase in healthcare costs
while awaiting revision surgery (Figure
1B).
Under the non-surgical option, the
patient is in the initial state before progres-
sion (i.e. in ACR class III) or post progres-
sion to functional dependency (i.e. in ACR
IV) or dead. Disease progression involves
increased healthcare resource consumption
and lower utility due to greater limitations
on physical function, less mobility and
more severe pain (Figure 1A). 
Under Delayed primary THR the
patient is referred to THR upon disease pro-
gression to functional dependence. Once
referred to THR the patient faces the same
risk of death due to surgery as patients of
the same age undergoing surgery in the first
place, although different gains in utility are
accrued, since utility would have declined
while waiting and greater gains are expect-
ed with surgery at lower pre-operative utili-
ty; the level of utility achieved after delayed
surgery is nevertheless lower than that after
immediate THR15 (Figure 1). 
The model defines cohorts by sex and
age with distinct revision risk profiles.
Health value is measured as Quality-
Adjusted Life Years (QALYs), whereby
each annual cycle is assigned a utility pay-
off, a preference based valuation of HRQoL
in the occupied health state, on a scale rang-
ing from a negative number (for states
worse than death), including zero (states
equivalent to death), to 1 (representing full
health). Under each treatment option, total
health value and costs are the sum of
QALYs and costs over the modelled life-
span of the cohort up to a maximum age of
100, and are discounted at an annual rate of
5%.16
A review of the research literature on
German settings was conducted to populate
model parameters on implant survival (rates
of implant revision operations by age and
sex groups) for primary and revision hip
replacement operations, distribution of type
of revision operations (aseptic loosening,
sepsis and other), surgical complications,
NSAID medication use by OA severity, rate
of OA disease progression under medical
therapy. The review also sought to identify
costs of primary THR, revision hip replace-
ment (RHR) and non-surgical therapy and
utilities for the states of post-operative suc-
cess, revision, successful revision, function-
ally dependent OA and functionally inde-
pendent OA.  
Literature review: identification of
studies
PRISMA principles were employed for
reviewing the existing literature.17,18
Searches were conducted in Medline and
Embase (via OVID), Cinahl (via EBSCO)
and Cochrane Library (including Cochrane
Systematic Reviews, the Database of
Abstracts of Reviews of Effects (DARE),
the National Health System Economic
Evaluation Database (NHS EED), and
Health Technology Assessment databases)
and ISI Web of Science, from inception to
end of May 2014. Search terms were con-
structed using free text, MeSH and the-
saurus terms (Appendix I). After deduplica-
tion of bibliographic records, titles and
abstracts were screened independently by
two reviewers. The full-text of potential rel-
evant articles was obtained. 
Articles were considered if they were
written in English or German. Articles
reporting information on: i) health out-
comes; ii) healthcare costs of prostheses
and THR surgery, complications, rehabilita-
tion, follow-up, revision, and non-surgical
management; iii) health state utilities; and
iv) indirect costs of OA disease or its treat-
ment were included. 
Health outcome studies had to report on
management of OA patients in routine prac-
tice. Evidence related to specific devices or
surgical techniques was not considered.
Studies with THR patient cohorts <100 or
with follow-ups<10 years were excluded.
Studies on healthcare and productivity costs
other than in German population were
excluded. Studies on health state utility
were included if reporting outcomes for OA
patients at different levels of disease sever-
ity, as defined by Harris Hip Score (HSS)
class or equivalent measures.
Details of the included study type, pop-
ulation, year, summary outcome measures
reported were extracted by one reviewer,
and verified by a second reviewer. 
All included studies were assessed for
methodological quality according to
Cochrane and Centre for Reviews and
Dissemination (CRD) guidance criteria for
conducting systematic reviews,19 adapted to
our aim to populate an economic model.
The overall quality of the studies and data
were synthesized through a narrative
review.
Literature review: results
The electronic search produced 2,865
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Figure 1. Markov chain with annual cycles for non-surgical and delayed treatment (A);
Markov model with annual cycles for total hip replacement (B).
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records on costs, and 12,990 records on
health or HRQoL outcomes. A screening of
titles and abstracts of these records
(Appendix II) identified 75 articles for full
text screening on health outcomes and 10
on cos Title and abstract and full text
screening identified 17 studies (19 articles)
on health-related outcomes and 8 studies on
direct and indirect (productivity) costs or
resource utilisation conducted in subjects
living in Germany that met the criteria for
inclusion in the review. A further 10 studies
were identified from manual searches of
reference lists from included studies and an
updated search on cost studies that omitted
the filter for osteoarthritis/ arthritis. 
Studies not meeting the inclusion crite-
ria for the sole reason of its country setting
being other than Germany were used to
populate model parameters for which data
from German populations were not avail-
able. 
Model inputs
Effectiveness parameter: implant survival
Five studies met the inclusion criteria
and reported results adequately (Kaplan and
Meier (K-M) implant survival curves).
Because none of these studies provided
nationally representative data, data on
implant survival from the National Joint
Registry (NJR) from England and Wales
were used as the most relevant alternative
source of mature data to German practice,
despite possible differences in the types of
cups used between the two countries.
Figure 2A compares the K-M implant
survival curves from German studies in the
under 65 age group with sex-specific NJR
data on individuals aged 55-64, whilst
Figure 2B presents the respective implant
survival curves from German studies in the
65+ group with the sex-specific NJR curves
in the 65-74 and 75+ groups. The NJR
curves track the path of the most recent
German study although there is an increas-
ing divergence from the 6th year. This
German study investigated the effect of 2nd
generation Metal-on-Metal prostheses
implanted as far back as 1994, whereas the
NJR data includes all THR operations per-
formed from 2003 onwards.21-25
Figure 3 illustrates the survival of
implanted hips for primary THR by age (55-
64 vs. 65-74) and gender, both overall and
by fixation method. Fully cementless had
lower survival than hybrid and cemented
implants, suggesting that acetabular cups
are driving their excess failure rate. The
higher rate of failure in the younger group
and among males is also evident in these
data on all operations performed in England
and Wales since 2003.21 The position of the
all THR curve relative to the curves for
cemented and cementless operations
reflects the predominant use of the former
fixation method in the older group, and the
primacy of the latter method among
younger patients. A conference abstract
recently published a 5-year implant survival
rate of 96.11% for 336,759 primary hip
replacements received by AOK members
during 2005-2011.26 In contrast, the corre-
sponding rates for all THRs in England and
Wales from the NJR data reviewed here
were 97.52%, while the cemented rate was
98.46% and the uncemented 96.35%.21 In
our decision analysis we used the NJR as
the best available source of implant survival
data to describe the experience in Germany;
the base case analysis adopted the ALL
THRs data and the sensitivity analysis, for
low and high revision rates, the cemented
and cementless data depicted in Figure 3.
Effectiveness parameter: complications
In-hospital deep vein thrombosis
(DVT), pulmonary embolism (PE) and
bleeding complication rates of 0.26%,
0.07% and 1.18% respectively were found
in an observational study across 99 centres
in Germany among 3,905 THR patients pro-
phylactically treated with fondaparinux.27
Approximately 4% were revision opera-
tions, and the majority of patients were aged
65 or older (no details were reported).
Data from the German national nosoco-
mial infection surveillance system for
43,463 procedures from 48 hospitals
revealed an event rate of severe surgical site
infections of 0.77 per 100 elective THR
surgeries.28 Surgical site infection rates for
primary THR in patients with arthrosis vary
between German hospitals by volume.29
Likewise, among 149,000 AOK OA
patients, the probability of 90-day DVT or
PE was 0.96% (0.85% for top and 1.35%
for bottom quintile volume).30 The respec-
tive figures for mortality are 0.56% (0.48%
and 0.93%) while, as expected in a sample
like this, where 75% of patients were older
than 63, femur fractures occurred at the
high rate of 0.73 (0.58 and 1.09). These and
other administrative data31 suggest that
health outcomes in routine German practice
may differ from those in other countries
such as Sweden and the UK.
We investigated the effects of excess
mortality associated with walking disability
in the functionally dependent state of the
medical therapy arm in sensitivity analysis,
where we applied a death hazard ratio of
1.27 [95% CI 1.10-1.47]), reported for
walking-aid users with OA.1,32-34 This figure
is consistent with findings from English
cohort35 and other data36 but contrary to
some reports37,38 (Appendix IV).
The values used to populate effective-
ness parameters are presented in Table 1.39-
47 The preferred sources and values are used
for the base case, whereas high and low val-
ues are used for sensitivity analyses.
German sources were used for short-term
complications of primary THR, whereas
UK registry data were used for revision risk
parameters. Since German data on short
term complications of Revision THR were
not available, these outcomes were imputed
from the outcomes for primary THR based
                             Review
Figure 2. Implant survival after primary total hip replacement in German experimental
studies and registry data for England and Wales, by age group [age <65 (A) and age 65+
(B)]. Sample numbers (number of hips) are: Bohm and Bosch 1998:22 at start n=264; 10
years n=9; 11 years (final) n=2. Gierse et al., 1996:23 at start n=106; at 14 years (final)
n=73. Neuerburg et al., 2012:20 at start n= 1270; at 10 years (final); at 5 years n=1024; at
10 years (final) n=286. Eingartner et al., 2007:24 at start n=250; 10 years n=158; 13 years
n=126; 14 years (final) n=30. Suckel et al., 2009:25 at start n=320; 17 years (final) n=97.
As for National Joint Registry 2014,21 at start, aged 55-64: Males n=63,806, Females
n=77,260; aged 65-74: Males n=86,400, Females n=130,789; aged 75+ Males n=61,604,
Females n=125,032.
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Table 1. Effectiveness model parameters.
Parameter                                                                           Value                                            Source
                                                          Base case                   Low                         High            
Primary THR       Peri-operative mortality:     0.0056                             0.0048                              0.0093                90-day mortality
                              <75 years                                                                                                                                             Base case: Overall rate;30
                                                                                                                                                                                             Low: hospitals in top quantile by procedure volume per year;30
                                                                                                                                                                                             High: hospitals in bottom quantile by procedure volume per year30
                              Peri-operative mortality:     0.0151                             0.0059                              0.0167                90-day mortality
                              ≥75 years                                                                                                                                             Base case: Mid-point between rates for men and women aged≥80
                                                                                                                                                                                             in England and Wales (NJR);40
                                                                                                                                                                                             Low: Mid-point between rates for men and women aged 75-79 in 
                                                                                                                                                                                             England and Wales (NJR);40
                                                                                                                                                                                             High: Mid-point between upper 95% CI limit of rates for men and
                                                                                                                                                                                             women aged ≥80 in England and Wales (NJR)40
Complications   Pulmonary embolous            0.0096                             0.0085                              0.0135                90-day complications
                                                                                                                                                                                             Base case: post-operative PE or DVT – OA sample;30
                                                                                                                                                                                             Low: Hospitals in top quintile volume of procedures performed per year;30
                                                                                                                                                                                             High: Hospitals in the bottom quintile volume of procedures 
                                                                                                                                                                                             performed per year30
                              Wound infection                     0.0084                             0.0077                              0.0159                Surgical site infections:
                                                                                                                                                                                             Base case: primary hip replacement for arthrosis in departments
                                                                                                                                                                                             performing >100 procedures per year;29
                                                                                                                                                                                             Low;28
                                                                                                                                                                                             High: Primary hip replacement for arthrosis in departments 
                                                                                                                                                                                             performing >50 and ≤100 surgeries per year29
                              Bleeding                                   0.0118                             0.0096                              0.0140                Base case;27
                                                                                                                                                                                             Low and High: +/-20%
                              Dislocation                              0.0239                             0.0191                              0.0287                Base case: 90-day rate of dislocation; 
                                                                                                                                                                                             Low and High:+/-20%
                              Revision rates                Years 1-11 (%),           Years 1-11 (%):             Years 1-11 (%):       Base case: Annual revision hazards from cumulative incidence function
                              by sex and age                 55-64 males:                 55-64 males:                   55-64 males:         (adjusted for competing death risk) for all primary hip replacement 
                              (55-64, 65-74 and                 0.88, 0.63,                 0.55, 0.42, 0.42,                .92, 0.68, 0.68          surgeries in England and Wales 2003-20012, digitally extracted
                              ≥75 - age groups)           0.60, 0.71, 0.64,             0.36, 0.37, 0.38,           0, 0.87, 0.88, 1.12,     from Figure 3.9 in NJR Annual Report 2014;21
                                                                         0.76, 0.73, 0.73,            0.38, 0.57, 0.58,              1.13, 0.72, 0.73,        Low: Annual revision hazards from Kaplan-Meier survival rates
                                                                         0.78, 0.67, 0.81;                  0.58, 0.58;                       ,0.73, 1.00;            of all cemented prostheses, Table 3.821
                                                                     females: 0.75, 0.58,     females: 0.47, 0.35,       females: 0.88, 0.62,    (years 2, 4, 6, 8, & 9 were calculated by interpolation
                                                                         0.65, 0.80, 0.77,            0.35, 0.40, 0.40,              0.62, 0.95, 0.96,        of the reported K-M rates at adjacent years);
                                                                         0.85, 0.94, 0.91,             0.39, 0.39, 0.55,              1.14, 1.16, 0.98,       High: Annual revision hazards from Kaplan-Meier survival rates
                                                                         0.92, 0.81, 0.81.             0.56, 0.56, 0.58.               0.99, 1.00, 1.00.        of all cementless prostheses, Table 3.821 (years 2, 6, 8, & 9 were c
                                                                                                                                                                                             alculated from interpolation of the reported K-M rates at adjacent years);
                                                                                                                                                                                             After 10 years, the annual hazard rate was assumed to be constant 
                                                                                                                                                                                             at the highest 10th year hazard value of the two sex groups within each
                                                                                                                                                                                             age group. Hazard rates for other groups are in Appendix III
Revision              Peri-operative                         0.0060                             0.0029                              0.0091                Base case, Low and High: calculated by the authors to equal the ratio
hip                        mortality: under 75                                                                                                                            of mortality risk in revisions to mortality risk in primary operations
replacement      Peri-operative                        0.0237                             0.0116                              0.0359                (2.23)43 times the respective value for primary operation 
                              mortality: 75+                                                                                                                                     (presented at the top of this table)
Complications   Pulmonary embolous            0.0153                             0.0135                              0.0215                Base case, Low and High: Ratio of Revision to Primary 90-day THR PE
                                                                                                                                                                                             risk,41 i.e. 1.59, times PE risk for primary THR
                              Wound infection                     0.0420                             0.0385                              0.0795                Base case, Low and High: Ratio of Revision to Primary 90-day THR specific
                                                                                                                                                                                             wound infection rate,41 i.e. 5, times primary wound infection rate
                           Dislocation in men            0.086                           0.029                            0.148               Base case: 90-day rate of dislocation (non OA specific);43
                           Dislocation in women      0.082                           0.027                            0.142               female to male OR: 0.95;
                                                                                                                                                                          Low: One third of base case;
                                                                                                                                                                          High: 6-month cumulative dislocation incidence44
                           Repeat Revision                 0.040                           0.036                            0.044               Base case:42,45  High/Low : +/- 10%
Medical            Natural rate of                   0.062                           0.040                            0.201               Base case and High: based on authors’ own estimates of transition
therapy             progression to                                                                                                                    after one year from primary data;46
                           functional dependence                                                                                                    Low: from geometric mean annual rate of transition of a 10-year
                           (i.e., ACR III to ACR IV)                                                                                                    cumulative incidence of functional dependence39
                           All-cause mortality         Sex and                       None                           None              Base case: Period life tables for Germany 2009/201147
                                                                   age-specific                         
                           Relative excess                     1                                  1                                 1.27                Base case and Low: Assumption;
                           mortality in ACR IV                                                                                                             High: Adjusted hazard ratio of walking aid use34
THR, total hip replacement; ACR, American College of Rheumatologists; OA, osteoarthritis.
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on the incidence of complications of revi-
sions relative to primary operations report-
ed in studies of large US administrative
data.41
Effectiveness parameter: quality of life
(utilities)
Due to the lack of data on utility values
in German populations, values from UK,
Finland and US studies were used. Table
248-64 presents the values used in the model.
Pre-operative and 12-month post-operative
values,54 measured by the Euro-Qol 5-
Dimension Questionnaire (EQ-5D),55 were
used to approximate the values of the states
before disease progression in the non-surgi-
cal arm and the successful primary THR
state in the model, respectively. The nega-
tive effects of delaying surgery on the utility
of the successful THR state was derived
from the difference in utility outcomes
between patients with pre-operative HHS
<40 and 70>HHS≥40.3,56 The base case val-
ues for the need of Revision Surgery and
Successful Revision states were populated
from preoperative and postoperative revi-
sion hip replacement EQ-5D values.57 Other
utility values were used for sensitivity ana-
lysis.58-63 Successul state utilities in the first
year after THR and RHR were equal to 12-
month post-operative values minus 3% to
account for the patient’s recovery from the
operation.64
Healthcare costs parameterss
Of the studies reporting THR costs in
Germany,52,65-71 the most representative
source reported costs and outcomes of 154
470 AOK insured THR patients with OA.71
The mean cost of primary surgeries in 2007-
2009 was €7,221 (including first-year costs
of inpatient treatment, €9,149). Revision
surgery had a mean cost of €12,573. The
additional costs of 90-day post-primary
surgery complications and their rates were:
dislocation, €3,697 in 2.39%; pulmonary
embolism or thrombosis, €3,141 in 0.45%,
femur fracture, €8,155 in 0.28%; and over-
all, €9106 in 3.84%. 
The average cost of aseptic revision
operations conducted between 2009 and
2012 at a single hospital was €4,380.72 This
estimate included the cost of surgery (63%
of the total) and normal ward (27%), includ-
ing physiotherapy, diagnostic tests, medica-
tions, intensive care unit, physician and
nursing staff.
The mean cost of 49 total hip revisions
for peri-prosthetic infection (26% occurred
1 year after implantation) in a Rostock hos-
pital was calculated as €29,331. and the
LOS was 52.7 days73,74 (relative to the 2013
DRG reimbursement rate of €24,201, cov-
ering the hospital cost of two-stage septic
revision,73 our chosen estimate appears con-
servative).
We have found no data on medication,
hospital or nursing home costs for severe
OA patients treated by non-surgical means.
We therefore imputed healthcare costs
based on costs from Italy3, adjusted for pur-
chasing power cost differences between
Italy and Germany.75
Table 371-86 presents the values used for
cost parameters. Good quality information
was found on costs of primary THR, health-
care in the first year post-primary THR, and
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Figure 3. Kaplan-Meier implant survival curves in National Joint Registry data for England and Wales. National Joint Registry Annual
Report data, Table 3.8, and chart (digitally extracted data), Figure 3.9.21 The curves for all total hip replacements are adjusted for com-
peting risks of death and may not be entirely comparable to the curves for fixation modes. Sample numbers (number of hips) for
cemented at start are: Age 55-64 male n=11,214; age 65-74 male n=31,396; age 55-64 female n=18,110; age 65-74 female n=56,158.
Sample numbers (number of hips) for cementless at start are: Age 55-64 male n=32,236; age 65-74 male n=36,055; age 55-64 female
n=39,357; age 65-74 female n=47,134. Numbers at risk after the start of follow up were not reported.
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Table 2. Utility values.
State                                                                              Base         High Low          Tool               Source
                                                                                                                case          Gain  Gain
Medical therapy     Utility before Progression (ACR III)              0.52                0.61     0.80             EQ-5D                  Base case: Mean pre-operative value of OA patients with no
                                                                                                                                                                  High Gain: TTO          EQ-5D anxiety/depression. Value is for males; females: 0.47;54
                                                                                                                                                                       Low: 15D                High: Mean moderate OA pre-determined state assessed by
                                                                                                                                                                                                        elective THR patients61
                                                                                                                                                                                                        Low: pre-operative mean from THR patients with 70>HHS≥4056
                                  Utility after Progression (ACR IV)                  0.28                0.39     0.77             EQ-5D                  Base case: Mean pre-operative value of OA patients with 
                                                                                                                                                                  High Gain: TTO          moderate/severe EQ-5D anxiety depression. Value presented is
                                                                                                                                                                   Low Gain: 15D           for males; females: 0.25;54
                                                                                                                                                                                                        High: Assumed equal to 66% of utility before progression
                                                                                                                                                                                                        value,60 and mean severe OA pre-determined state assessed by
                                                                                                                                                                                                        elective THR patients;59
                                                                                                                                                                                                        Low: pre-operative utility from THR patients with HHS<4056
Primary THR           Annual Successful primary THR                      0.83                0.96     0.86             EQ-5D                  Base case: Mean post-operative value in patients with no
                                                                                                                                                                  High Gain: TTO          pre-operative anxiety/depression on EQ-5D. Value is for males;
                                                                                                                                                                   Low Gain: 15D           the value for females is 0.80;54
                                                                                                                                                                                                        High: Mean 12-month post-operative values;61
                                                                                                                                                                                                        Low: Patients undergoing primary THR & 70>HHS≥40 in Finland
                                                                                                                                                                                                        (value is mean at 12 months for age 60-75; age 50-59, 0.90; age
                                                                                                                                                                                                        75+, 0.81).56 Includes 3% reduction in 1st post-operative year
                                                                                                                                                                                                        utility due to rehabilitation64
                                  Pre-operative revision hip replacement       0.35                0.49     0.81             EQ-5D                  Base case;58
                                                                                                                                                                  High Gain: TTO          High;61
                                                                                                                                                                   Low Gain: 15D           Low: Mean 12 month post-operative values of Finish patients
                                  Successful RHR                                                   0.64                0.67     0.82                                            undergoing RHR56 (presented value is for age 60-75; age 50-59, 
                                                                                                                                                                                                        0.86; age 75+, 0.80). Includes 3% reduction in first post-operative
                                                                                                                                                                                                        year to account for effect of rehabilitation64
Delayed THR          Pre-operative States ACR III/IV           Same as for THR                                                                   Base: Utility of annual successful THR minus the utility
                                  Utility post-primary THR                                   0.79                0.85     0.84         Assumption             difference 12-month post-operatively between HHS<40 and 
                                                                                                                                                                High: Assumption        HHS>=40 and <7056 scaled up by the ratio of EQ-5D to 15D
                                                                                                                                                                       Low: 15D                impact of hip/knee arthrosis.65 Value is for males; females, 0.76;
                                                                                                                                                                                                        High: Utility of annual successful THR minus the product of the
                                                                                                                                                                                                        regression to the mean coefficient from pre to 12 month post- 
                                                                                                                                                                                                        operative utility scores times the difference in medical therapy 
                                                                                                                                                                                                        utility before and after progression.3
                                                                                                                                                                                                        Low: Mean at 12 months post-operatively,56 patients undergoing 
                                                                                                                                                                                                        primary THR with HHS<40 in Finland. Includes 3% reduction in 1st
                                                                                                                                                                                                        post-operative year due to effect of rehabilitation64
THR, total hip replacement; ACR, American College of Rheumatologists; TTO, time trade-off technique; OA, osteoarthritis; 15D, 15 dimensional utility index; EQ-5D, EuroQol 5 dimension index; HHS, Harris hip score.
revision THR. The only source of German
data found for costs under the Medical
arm76 was of a lower reporting quality than
the UK available source,77 and was there-
fore used for sensitivity analysis, while UK
resource use quantities77 valued at German
prices were used for the base case analysis.
Due to limited data available on indirect
costs78,79 and nursing care costs,80 these
costs were not considered in the analysis. 
Model results
Base case results
Table 4, presents base case results by
gender for two hypothetical individuals, of
age 55 and age 65 at the time of the decision
whether to a) undergo timely THR, b) delay
THR until physical condition deteriorates,
and c) treat by medical therapy indefinitely.
The costs are in Euros as at 2013 and the
benefits in quality adjusted life years
(QALYs), both discounted at 5% per year.
Undiscounted costs and QALY figures are
also presented in the table. 
Undiscounted costs highlight the costs
to a decision maker who values outcomes in
the future as much as outcomes in the pres-
ent. For such policy-maker, timely THR
results in net healthcare cost savings for
women aged 55 whereas it results in posi-
tive net costs for 55 year old men and for 65
year olds, relative to delayed THR and med-
ical therapy. Undiscounted QALYs results
reveal that a timely THR policy represents
an average gain to an individual patient
equivalent to between 3.15 extra years of
life in full health for a 65 year old male, and
3.93 extra years of life in full health for a 55
year old female. 
Timely THR is associated with ICERs
below €2,000 in all instances, relative to
Medical therapy or delayed THR. In all
cases, undergoing THR whether timely or
with delay results in additional (discounted)
costs to the SHI system. Further, undergo-
ing timely THR incurs additional costs rela-
tive to delayed THR. In a 55 year-old
woman timely THR is expected to cost the
SHI €4,782 more, on average, than if she
was managed non-surgically; on the other
hand, if she were turned away from surgery
until her condition deteriorated to the extent
of losing her functional independence
(which at the base case rate of disease pro-
gression, 6% per year, implies a median
delay of 11 years), her lifetime treatment
would cost €1,363 more than non-surgical
therapy. The resulting saving to the SHI
from delaying THR, of €3,419, comes with
a high cost to the patient since her benefits
from delayed THR are only 2.86 (discount-
ed) QALYs, instead of the 5.55 (discounted)
QALYs with timely THR. Thus, the incre-
mental cost per quality adjusted life year of
timely THR is €1,270 per patient (see foot-
note o of Table 4 for this figure). 
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Sensitivity analyses 
Table 5 presents the results of determin-
istic sensitivity analyses for the most influ-
ential model parameters. The utility gain
with primary THR and the costs of primary
THR (including implant costs) had the
largest effects on the results, but ICERs
remained below €9,000 in the most conser-
vative scenarios. In comparison with the
base case results, reproduced in the top row,
the ICER for the delayed THR option rela-
tive to medical therapy is larger when THR
extends survival, in the bottom row. The
reason for this increase is that the severely
affected patients who now die earlier under
medical therapy consume a disproportion-
ately large amount of healthcare resources.
We performed a two-way sensitivity analy-
sis to identify the minimum reduction in
medical therapy costs at which life exten-
sion with THR resulted in a lower ICER
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Table 3. Unit costs (annual estimates in 2013 expressed in €).
Cost                                                              Base case    Lower             Upper          Source
Primary THR- prosthesis and surgery                            7221              4582                    11,944             Base case;71
                                                                                                                                                                           Lower: uncomplicated THR;82
                                                                                                                                                                           Upper: mean +1.96 SD82
Cost of RHR                                                                        12,573            4380                    29,331             Base case: Revision operations within the first year of primary surgery;71
                                                                                                                                                                           Lower: Cost of aseptic loosening;72
                                                                                                                                                                           Upper: Septic revision73
Medication use in successful state -                                154                 83                         723                Base case: As for ‘medical therapy for severe OA’, except for proportion of 
1st year after primary surgery or revision                                                                                             NSAID use: 0.478, where 0.08 at ≥90% of the year, and rest, 0.398, at (assumed,
                                                                                                                                                                           midpoint) 40% of the year;77
                                                                                                                                                                           Lower/Upper: As Base case but with low/high NSAID prices
Monitoring and rehabilitation and inpatient                3733              2986                      4480               Base case: In-patient hospitalization costs in the first year post-surgery 
hospital use in the year after THR                                                                                                             (€1928)71 + 20% of total cost of surgery with rehabilitation (€1805);66 i.e., 
                                                                                                                                                                           base case THR/0.80x0.20 (does not include planned outpatient follow-up visits; 
                                                                                                                                                                           92% of patients do not require follow of care in the first year);
                                                                                                                                                                           Lower/upper: +/- 20%
Medication use in successful                                            117                 63                         550                Base case: as in annual cost of medical therapy for severe OA except for
THR -2nd + years after primary                                                                                                                 proportion of NSAID use: 0.34, where 0.08 at 90% or more, and rest, 0.26 at 
                                                                                                                                                                           assumed, midpoint) 40% of the year77 
                                                                                                                                                                           (costs applicable to states before revision);
                                                                                                                                                                           Lower/Upper: As Base case but with high NSAID prices
Hospitalisations and                                                           327                233                        420                Base case: unpublished data;83 assumes equal to costs of Hospitalisations
physiotherapy-2nd year after surgery                                                                                                       before progression times ratio of hospital costs ACR II to ACR III in RA.84 
                                                                                                                                                                           Adjusted to German prices using relative price indices for health care (Fig. 6 in85);
                                                                                                                                                                           Lower/Upper: 20% decrease/increase in hospital costs, 50% decrease/increase
                                                                                                                                                                           physiotherapy costs
Medical therapy for severe OA                                         233                125                        984                Base case: NSAIDs consumption, Ibuprofen 2.4 mg/day, before THR, 90% and 40% of
                                                                                                                                                                           the year in 21% and 40% of patients, respectively;77 3 specialist visits. Includes cost 
                                                                                                                                                                           of Gastro Protective Agents (GPA) and pre-administration tests;*
                                                                                                                                                                           Lower: Nimesulide Ganules 30 bags of 100 MG (Sachet), 100 mg 2 x day;
                                                                                                                                                                           Upper: Lower 95% CI of mean costs of medications, outpatient physician visits and 
                                                                                                                                                                           non-physician services80 reflated to 2013 prices°
Medical therapy for severe OA –                                     434                233                       1308               Base case: NSAIDs use 90% & 40% of the year by 50% of patients each –assumed;77
with disease progression                                                                                                                           3 specialist visits. Includes cost of Gastro Protective Agents (GPA) 
                                                                                                                                                                           and pre-administration tests;*
                                                                                                                                                                           Lower: Nimesulide Ganules 30 bags of 100 MG (Sachet), 100 mg 2 x day;
                                                                                                                                                                           Upper: mean costs of medications, outpatient physician visits and non-physician
                                                                                                                                                                           services;80 reflated to 2013 prices°
Hospitalisations and physiotherapy for severe OA      561                393                        728                Base case:83 and unpublished data, imputed based on ratio of ACR III to ACRII 
                                                                                                                                                                           hospital costs in RA.84 Adjusted to German prices using relative price indices for 
                                                                                                                                                                           health care (Fig. 6 in85);
                                                                                                                                                                           Lower/Upper: 20% decrease/increase in hospital costs, 50% decrease/increase 
                                                                                                                                                                           Physiotherapy costs
Hospitalisations and                                                           832                563                       1101               Base case:83 and unpublished data, imputed based on ratio of ACR IV to ACRII
physiotherapy for severe OA –                                                                                                                  hospital costs in RA.84 Adjusted to German prices using relative  price indices for 
with disease progression                                                                                                                             health care (Fig. 6 in85);
                                                                                                                                                                           Lower/Upper: 20% decrease/increase in hospital costs, 50% decrease/increase
                                                                                                                                                                           physiotherapy costs
Complications primary THR:                                            3141              2513                      3769               Cost per (90-day post-operative) event;
DVT or PE                                                                                                                                                         Base: thrombosis or pulmonary embolism71
                                                                                                                                                                           Lower/upper=+/-20%
THR, total hip replacement; RHR, revision hip replacement; NSAID, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; DVT, deep vein thrombosis; PE, pulmonary embolism; ACR, American College of Rheumatologists. *Includes vis-
its to specialist in proportion to drug use. GPA prophylaxis and treatment costs were derived from NSAIDs costs and iatrogenic cost multiplier.83 Other drug (corticosteroids and analgesics) costs were derived by the same approach. °OA
patients, not hip OA specific. Reflated using the Consumer Price of Health (sector 06) reported by Federal Statistical Office of Germany 2014; https://www.destatis.de/EN/FactsFigures/NationalEconomyEnvironment/Prices/Consumer
PriceIndices/86
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than the base case ICER; medical therapy
costs (other than adverse events) would
need to be 50% lower than under the base
case in order for life extension with THR to
translate in an improved ICER for the THR
options relative to medical therapy. Notice
that, in Table 5, the ICER of THR is relative
to Delayed THR, as opposed to Medical
Therapy, and is not affected by structural
uncertainty about survival benefits, since no
physical functioning dependence for a peri-
od longer than a year, and therefore
increased death risk, is experienced under
any of the two surgical options.
Discussion
Our systematic search of the epidemio-
logical and health services research litera-
ture sought to populate a cost-effectiveness
model of end-stage OA treatment in
Germany.
Implant revision rates from the national
registry for England and Wales were used in
the economic model, since no nationally
representative data on the revision rates of
THR in Germany were identified.
Treatment practice in England and Wales
was thought to be similar to that of
Germany in terms of mode of fixation and
implant selection and the national registry
measured outcomes over a follow-up of ten
years. Moreover, such data displayed
implant survival curve profiles that were
similar to the most recent German study in
the relevant population.
The analysis was robust to a wide-range
of variation in the preference valuation of
generic health-related quality of life out-
comes, and therefore uncertainty due to the
lack of such data from German OA patients.
Limited information on healthcare costs
for the medical therapy arm were found for
Germany and were complemented with
detailed data from the UK providing a range
of plausible variation for sensitivity analy-
sis. We could not find any study document-
ing productivity costs. Nevertheless recent
evidence on productivity benefits for hip87
and knee replacement,88 suggests that THR
has benefits beyond those realised in the
healthcare system.
In our conservative analysis timely
THR costs more to SHI than medical thera-
py and delayed THR. The expected benefit
of having timely THR in terms of health
related quality of life to patients is substan-
tial, ranging from the equivalent of an addi-
tional 3.15 years of life in full health for a
65 year-old male person to 3.93 extra years
of life in full health for a 55 year-old
woman. This is remarkable given that (in
the base case) THR produces no survival
benefits (and a small excess peri-operative
mortality risk) over medical therapy, so that
all the QALY gain is due to the effects on
quality of life. In sensitivity analyses we
accounted for new evidence that walking
disability is associated with reduced life
expectancy, by accounting for an excess
mortality risk after progression to a func-
tionally dependent state under the medical
therapy arm, so that in effect THR increases
quantity, as well as quality, of life by avoid-
ing disease progression.34
An observational study of THR relative
to medical therapy in OA Medicare patients
in the US, found that THR reduced mortali-
ty, heart failure and diabetes risk at 1 year
and every two years until the 7-year end of
study follow-up and increased cumulative
OA and non-OA related healthcare non-pre-
scription drug costs by US$6,366.89 In our
sensitivity analysis, survival benefits with
THR improved its cost-effectiveness only if
the counterfactual costs of medical therapy
for severe OA under non-surgical therapy
were less than €117 annually.
The only relevant existing study in
Germany used long-term costs and benefit
extrapolations from 6-month HRQoL out-
comes and hospital resource utilisation by a
group of 261 mostly OA patients of mean
age 68 following primary or revision (n=10)
THR.90 It found that THR resulted in addi-
tional undiscounted QALYs of 5.95 relative
to medical therapy and that more severe
patients (i.e. low WOMAC scores) had larg-
er QALY gains than patients with high
WOMAC scores. In our study timely THR
Table 4. Results: costs (expressed in €) and quality-adjusted life-years by sex and age at point of initial surgery decision (discounted at
5% annual rate, unless indicated otherwise).
Age group                   Measure                          THR            Delayed THR               Medical therapy  Difference
                                                                                                                                                                             THR- medical           Delayed
                                                                                                                                                                                                          THR – medical
Females Age 65          Costs undiscounted                       20,362                       19,629                                        18,338                                       2,024                            1,291
                                      QALYs undiscounted                       14.58                         11.04                                           7.37                                          7.20                              3.67
                                        Discounted Costs                         16,892                       13,484                                        11,515                                       5,377                            1,969
                                        Discounted QALYs                          9.50                           6.96                                            4.98                                          4.52                              1.97
                                                    ICER                                          -                                 -                                                  -                                           1,190*                             999
Females Age 55          Costs undiscounted                       27,474                       27,083                                        28,263                                        -789                            -1,181
                                      QALYs undiscounted                       20.68                         16.74                                          10.26                                        10.42                             6.49
                                        Discounted Costs                         19,607                       16,189                                        14,826                                       4,782                            1,363
                                        Discounted QALYs                         11.56                          8.86                                            6.00                                          5.55                              2.86
                                                    ICER                                          -                                 -                                                  -                                             861°                              476
Males Age 65               Costs undiscounted                       19,062                      17,3714                                       15,538                                       3,524                            1,832
                                      QALYs undiscounted                       12.50                          9.35                                            6.42                                          6.08                              2.93
                                        Discounted Costs                         16,298                       12,347                                        10,193                                       6,105                            2,153
                                        Discounted QALYs                          8.49                           6.16                                            4.51                                          3.98                              1.65
                                                    ICER                                          -                                 -                                                  -                                           1,533#                           1,307
Males Age 55               Costs undiscounted                       24,964                       24,168                                        24,264                                         700                                -96
                                      QALYs undiscounted                       18.13                         14.42                                           9.07                                          9.06                              5.35
                                        Discounted Costs                         18,684                       15,095                                        13,450                                       5,234                            1,644
                                        Discounted QALYs                         10.65                          8.06                                            5.56                                          5.09                              2.49
                                                    ICER                                          -                                 -                                                  -                                           1,029§                             659
THR, total hip replacement; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio. *ICER vs Delayed THR=1,338; °ICER vs Delayed THR=1,270; #ICER vs Delayed THR=1,692; §ICER vs Delayed
THR=1,385.
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for a 65 year-old had undiscounted QALY
gains relative to medical therapy of 6.08 for
men and 7.20 for women. In contrast, we
found larger QALY gains for timely than
among delayed therapy despite the more
severe status of patients at the time of
delayed THR and allowance in our analysis
for larger pre to post-operative health gains
of patients with more severe disease.48 The
reason for the different results between the
two studies is that delayed THR arm in our
study measured the expected QALY gains at
the time the decision between timely,
delayed or no surgery is made, whereas the
results by disease severity reported by
Vogl90 are calculated at the time patients are
operated and therefore, unlike our results,
miss the loss in utility during any delay of
treatment experienced by the more severe
patients. 
Vogl and colleagues found that THR
was associated with positive undiscounted
incremental costs of €7,730 relative to med-
ical therapy, and reported higher costs
among patients with more severe disease.90
The undiscounted incremental costs of
timely THR in a 65 year old in our analysis
were instead €2024 in females, and €3,524
in males. The difference with our results is
due to Vogl’s assumption that the non-surgi-
cal costs in the THR arm were equal to
those of the medical arm, whereas we
accounted for higher non-surgical health-
care costs in the medical therapy arm than
under timely THR, especially after disease
progression. Further, our total costs of time-
ly THR were higher than those of delayed
THR. Unlike the analysis by Vogl and col-
leagues, in delayed THR a proportion of
patients aged 65 years at the model baseline
would die without undergoing surgery and
therefore not incur the costs of primary
THR. Moreover, discounting reduces the
costs of the delayed arm, relative to timely
THR, because primary surgery occurs later.
Thus, at the 3.5% annual rate of discount
used by Vogl for deriving their reported
incremental cost per QALY with THR of
€1,669,90 timely THR has a respective fig-
ure of €901 in females and €1,341 in males
aged 65. 
Conclusions
In conclusion timely THR in Germany
is a cost-effective treatment policy under all
plausible values of uncertain model param-
eters. Delayed THR represents an ineffi-
cient use of scarce healthcare resources.
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